PeterArthurCalabresiMD

Neuroimmunology/Multiple Sclerosis

Professor of Neurology and Neuroscience, Johns Hopkins University School of Medicine; Director, Division of Neuroimmunology, Director, The Johns Hopkins Multiple Sclerosis Center

Join to view full profile

Dr. Calabresi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Calabresi's full profile

Already have an account?

Office
601 North Caroline Street
Baltimore, MD 21287
Phone+1 410-955-9441

Fax+1 410-955-6402

Summary

Dr. Peter Calabresi is a neurologist in Baltimore, MD and is affiliated with multiple hospitals in the area, including Johns Hopkins Bayview Medical Center and Johns Hopkins Hospital. He received his medical degree from Warren Alpert Medical School of Brown University and has been in practice 29 years. He specializes in neuroimmunology/multiple sclerosis and is experienced in general neurology, optical coherence tomography, magnetic resonance imaging, and neuroimmunology (multiple sclerosis).

Education & Training

University of Rochester Medical CenterResidency, Neurology, 1990 - 1993
University of Rochester Medical CenterResidency, Internal Medicine, 1988 - 1990
The Warren Alpert Medical School of Brown UniversityClass of 1988

Certifications & Licensure

FL State Medical License 2021 - Present
MD State Medical License 2000 - 2026
NC State Medical License 2020 - 2022
RI State Medical License 1997 - 2001
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2012-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Top Doctors:Baltimore Area Castle Connolly, 2012
Top Doctors:Washington-Baltimore Castle Connolly, 2012
Join now to see all

Clinical Trials

Safety and Immunologic Effect of Low Dose Versus High Dose Vitamin D3 in Multiple Sclerosis Start of enrollment: 2010 Mar 01
Completed
Phase 1
Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis Start of enrollment: 2010 Aug 01
Withdrawn
Phase 3
Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis Start of enrollment: 2020 Jun 11
ACTIVE_NOT_RECRUITING

Publications & Presentations

PubMed

Bile acid metabolites predict multiple sclerosis progression and supplementation is safe in progressive disease.
Dimitrios C Ladakis, Kimystian L Harrison, Matthew D Smith, Krista Solem, Sachin Gadani
Med. 2025-03-14
Multicenter Automated Central Vein Sign Detection Performs as Well as Manual Assessment for the Diagnosis of Multiple Sclerosis.
A R Manning, V Letchuman, M L Martin, E Gombos, T Robert-Fitzgerald
AJNR. American Journal of Neuroradiology. 2025-03-04
1 citations
Multiple Sclerosis and Other Acquired Demyelinating Diseases of the Central Nervous System.
Michael D Kornberg, Peter A Calabresi
Cold Spring Harbor Perspectives in Biology. 2025-03-03

Journal Articles

Brain and Retinal Atrophy in African-Americans Versus Caucasian-Americans with Multiple Sclerosis: A Longitudinal Study
Dorlan Kimbrough, Elliot Frohman, Laura Balcer, Ellen M Mowry, Daniel S Reich, Peter A Calabresi, Shiv Saidha, Teresa C Frohman, Elias S Sotirchos, Natalia Gonzalez Ca..., Brain

Press Mentions

Research Highlights from ACTRIMS Forum 2023March 30th, 2023
Going Viral at ACTRIMS 2023March 6th, 2023
Researchers Identify Inflamed Brain Cells Likely Involved in MS Nerve DegenerationSeptember 24th, 2021
Join now to see all

Grant Support

Imaging Neurodegeneration in Multiple SclerosisJOHNS HOPKINS UNIVERSITY2013–2029
Imaging Neurodegeneration in Multiple SclerosisJOHNS HOPKINS UNIVERSITY2013–2029
Mechanisms by which effector T cells modulate endogenous remyelinationJOHNS HOPKINS UNIVERSITY2000–2025
Mechanisms by which effector T cells modulate endogenous remyelinationJOHNS HOPKINS UNIVERSITY2000–2025
Mechanisms by which effector T cells modulate endogenous remyelinationJOHNS HOPKINS UNIVERSITY2000–2025
Mechanisms by which effector T cells modulate endogenous remyelinationJOHNS HOPKINS UNIVERSITY2000–2025
Validation of Serum Neurofilament Light Chain as a Prognostic and Monitoring Biomarker in Multiple SclerosisJOHNS HOPKINS UNIVERSITY2020–2024
Mechanisms Of Neurodegeneration And Strategies For Neuroprotection In MSNational Center For Research Resources2007–2011
Atorvastatin Therapy In Early Multiple SclerosisNational Center For Research Resources2007
Analysis Of The Axonal Degeneration Following Inflammatory Demyelination In MultNational Center For Research Resources2006–2007
Avonex Combination Trial (ACT)National Center For Research Resources2005–2007
Phase II/III Study Of Rituximab In Adults With MSNational Center For Research Resources2005